Cynata Therapeutics Limited (51S) Stock Price & Analysis
51S Stock Chart & Stats
- Day’s Range
- EUR 0.14 - EUR 0.14
- 52-Week Range
- EUR 0.06 - EUR 0.24
- Previous Close
- EUR 0.14
- Volume
- 0
- Average Volume (3M)
- 1,091
- Market Cap
- EUR 2.53M
- Enterprise Value
- EUR 2.43M
- Total Cash (Recent Filing)
- EUR 897.42K
- Total Debt (Recent Filing)
- EUR 0
- Price to Earnings (P/E)
- ―
- Beta
- -1.29
- Next Earnings
- Feb 25, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance Sheet
Zero debt reduces interest obligations and refinancing exposure, giving the company more flexibility than a similarly loss-making business with leverage. This provides some capacity to direct future funding toward clinical development, although it does not remove the need for external capital.
High Gross Margin Potential
A near-100% gross margin in several years indicates that direct costs have not been the primary constraint on the platform’s economics. If clinical programs and commercial activity scale successfully, this cost structure could support attractive contribution margins before operating expenses.
Scalable Off-the-shelf Cell Therapy Platform
An allogeneic, off-the-shelf approach is designed to support broader availability than patient-specific cell production, while the Cymerus platform provides a common manufacturing basis across multiple inflammatory and immune-mediated programs. That creates potential for platform reuse.
Bears Say
Persistent Losses And Weak Operating Performance
Persistent losses that are large relative to revenue show that the company has not yet converted its development platform into sustainable operating earnings. Continued negative margins can consume capital for several quarters and make future progress dependent on successful clinical and commercial execution.
Ongoing Cash Burn And Funding Dependence
Repeatedly negative operating and free cash flow means core activities are not funding themselves, leaving the company reliant on external financing to maintain operations and development programs. Even with a lower recent burn rate, continued cash consumption can restrict strategic flexibility.
Material Deterioration In Capital Base
The shift from positive equity to a negative balance and the sharp reduction in total assets indicate substantial cumulative value erosion. A smaller capital base can constrain operating runway and reduce resilience, making future financing more important to preserve continuity.
Cynata Therapeutics Limited News
Cynata’s CYP-001 GvHD Trial Terminated: What Investors Should Know
Cynata Therapeutics Limited ($CYYNF) announced an update on their ongoing clinical study. The phase II study A Multicenter, Randomized, Double-blind, Placebo-Controlled Phase II Study tested CYP-001 with standard steroid therapy
51S FAQ
What was Cynata Therapeutics Limited’s price range in the past 12 months?
What is Cynata Therapeutics Limited’s market cap?
When is Cynata Therapeutics Limited’s upcoming earnings report date?
How were Cynata Therapeutics Limited’s earnings last quarter?
Is Cynata Therapeutics Limited overvalued?
Does Cynata Therapeutics Limited pay dividends?
What is Cynata Therapeutics Limited’s EPS estimate?
How many shares outstanding does Cynata Therapeutics Limited have?
What happened to Cynata Therapeutics Limited’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Cynata Therapeutics Limited?
What is the TipRanks Smart Score and how is it calculated?
Cynata Therapeutics Limited Stock Smart Score
Company Description
Cynata Therapeutics Limited
Headquartered in Cremorne, Australia, Cynata Therapeutics Limited, established in 2003 and formerly known as Eco Quest Limited until its 2013 rebranding, specializes in the development and commercialization of its proprietary Cymerus mesenchymal stem cell technology for human therapeutic applications. Its most advanced therapeutic candidate, CYP-001, has successfully concluded Phase I clinical trials for graft versus host disease. The company's pipeline also includes CYP-004, currently in Phase III trials for osteoarthritis treatment, and CYP-006TK, an innovative polymer-coated silicon wound dressing designed for diabetic wounds. Furthermore, Cynata is advancing therapies for a broad spectrum of conditions such as asthma, heart attacks, coronary artery disease, acute respiratory distress syndrome, brain cancer, sepsis, critical limb ischemia, idiopathic pulmonary fibrosis, and renal transplantation. Cynata maintains a crucial strategic alliance with Fujifilm, which is responsible for the clinical and commercial manufacturing and supply of its Cymerus therapeutic mesenchymal stem cell products.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Kilian Kelly
- Employees
- 0
- Website
- www.cynata.com
- Address
- 100 Cubitt Street, Cremorne, VIC, 3121, AU
Cynata Therapeutics Limited (51S) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 3 | 14 |
| Technical Analysis | 4 | 3 | 3 |
| Moving Averages | 1 | 0 | 11 |
